Fdg uptake, tumour characteristics and response to therapy a review

Nuclear Medicine Communications

Volumn 19, Issue 2, 1998, Pages 97-106

  Smith, T A D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER; HEXOKINASE;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYME REGULATION; GLUCOSE TRANSPORT SYSTEM; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PREDICTION; RADIOISOTOPE DIAGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR SCINTISCANNING;

EID: 0031958510     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199802000-00002     Document Type: Article

References (89)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 306-314.
2. Reivich M, Alavi A, Wolf A et al. Glucose metabolic rate kinetic model parameters determination in humans: The lumped constants and rate constants for [18F]fluorode-oxyglucose and [1lC]deoxyglucose. J Cereb Blood Flow Metab 1985; 5: 179-192.
3. Strauss LG, Conti PS. The applications of PET in clinical oncology. J NucI Med 1991; 32: 623-648.
4. Hawkins RA, Hoh CK. PET FDG studies in oncology. NucI Med Biol 1994; 21: 739-747.
5. Wahl RL, Hawkins RA, Larson SM et al. Proceedings of a National Cancer Institute Workshop: PET in oncology - a clinical research agenda. Radiology 1994; 193: 604-606.
6. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurol Oncol 1992; 12: 159-165.
7. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglu-cose imaging: A method to assess the proliferative activity of human cancer in vivo. Cancer 1988; 61: 1776-1781.
8. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur j Cancer 1995; 31: 1924-1927.
9. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J NucI Med 1989; 15: 61-66.
10. Wahl RL, Zasadny KR, Helvie M, Hutchins GD, Weber M, Cody R. Metabolic monitoring of breast cancer chemo-hormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
11. Hoekstra OS, Ossenkoppele GJ, Golding R. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J NucI Med 1993; 34: 1706-1710.
12. Reisser C, Haberkorn U, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumours. f Otolaryngol 1993; 22: 231-238.
13. Haberkorn U, Strauss LG, Dimitrakopoulou A et al. Fluoro-deoxyglucose imaging of advanced head and neck cancer after chemotherapy. J NucI Biol 1993; 34: 12-17.
14. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-1477.
15. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglu-cose and positron emission tomography in colorectal cancer liver metastasis: Correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 691-696.
16. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988; 29: 1521-1525.
17. Chaiken L, Rege S, Hoh C et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 455-464.
18. Ichiya Y, Kuwabara Y, Sasaki M et al. A clinical evaluation of FDG-PET to assess the response to radiation therapy of bronchogenic carcinoma. Ann Nucl Med 1996; 10: 193-200.
19. Ichiya Y, Kuwabara Y, Otsuka M et al. Assessment of response to cancer therapy using fluorine-18-fluorode-oxyglucose and positron emission tomography. J Nucl Med 1991; 32: 1655-1660.
20. Jones DN, McCowage GB, Sostman HD et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996; 37: 1438-1444.
21. Okada J, Oonishi H, Yoshikawa K et al. FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med 1994; 8: 109-113.
22. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: A comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997; 38: 280-287.
23. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36: 1854-1861.
24. Brown RS, Fisher SJ, Wahl RL. Autoradiographic evaluation of the intratumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. J Nucl Med 1993; 34: 75-82.
25. Di Chiro G, DeLaPaz RL, Brooks RA et al. Glucose utilization by [18F]-fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
26. Floridi A, Paggi MG, Fanciulli M. Modulation of glycolysis in neuroepithelial tumours. J Neurosurg Sci 1989; 33: 55-64.
27. Torizuka T, Tamaki N, Inokuma T et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817.
28. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurements of local cerebral glucose metabolic rate in humans with [18F]-2-fluoro-2-deoxy- D-glucose: Validation of method. Ann Neurol 1979; 6: 371-388.
29. Okazumi S, Isono K, Enomoto K et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 333-339.
30. Marshall MJ, Goldberg DM, Neal FE, Millar DR. Enzymes of glucose metabolism in carcinoma of the cervix and the endometrium of the human uterus. Br Cancer 1978; 37: 990-1001.
31. Laubenbacher C, Saumweber D, Wagner-Manslau C et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinoma. J Nucl Med 1995; 36: 1747-1757.
32. Nagamatsu S, Nakamichi Y, Inoue N, Inoue M, Nishino H, Sawa H. Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J 1996; 19: 477-482.
33. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncol 1992; 3: 91-115.
34. Burger C, Wick M, Brusselbach S, Muller R. Differential induction of ‘metabolic genes’ after mitogen stimulation and during normal cell cycle progression. J Cell Sci 1994; 107: 241-252.
35. Greiner EF, Guppy M, Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production, J Biol Chem 1994; 269: 31484-31490.
36. Netzker R, Herfisse U, Wein KM, Brand K. Expression of glycolytic isozymes in rat thymoctes during cell cycle progression. Biochem Biophys Acta 1994; 1224: 371-376.
37. Pelka-Fleischer R, Fleischer W, Wilmanns W, Sauer H, Schalhorn A. Relation between cell cycle stage and the activity of DNA-synthesising enzymes in cultured human lymphoblasts: Investigations on cells separated according to DNA content by way of a cell sorter. Leukemia 1989; 3: 380-385.
38. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, de Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study. Radiology 1987; 164: 521-526.
39. Haaparanta M, Paul R, Huovinen Ret al. Pharmacokinetics and metabolism of 2-[18F]fluoro-2-deoxy-t>glucose (FDG) in mammary tumors of antiestrogen-treated rats. Nucl Med Biol 1995; 22: 483-489.
40. Watanabe A, Tanaka R, Takeda N, Washiyama K. DNA synthesis, blood flow, and glucose utilization in experimental rat tumors. J Neurosurg 1989; 70: 86-91.
41. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. Glut 1 expression in human breast carcinoma: Correlation with known prognostic markers. Anticancer Res 1995; 15: 2895-2898.
42. Haberkorn U, Ziegler SI, Oberdorfer F et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21: 827-834.
43. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: Correlation between Glut 1 expression and FDG uptake. J NucI Med 1996; 37: 1042-1047.
44. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J NucI Med 1993; 34: 414-419.
45. Minn H, Clavo AC, Grenman R, Wahl RL. In-vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J NucI Med 1995; 36: 252-258.
46. Smith TAD, Titley J, Eccles SA, Court W, McCready VR. The relationship between deoxyglucose uptake and the growth rate of tumors in-vitro (abstract). J NucI Med 1997; 38: 1046.
47. Bissonette P, Gagne H, Blais A, Bartleloot A. 2-Deoxyglu-cose transport and metabolism in CaCo-2 cells. Am j Physiol 1996; 270: G153-G162.
48. Mahraouil L, Rodolosse A, Barbat A et al. Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in CaCo-2 clones in relation to cell growth and glucose consumption. Bio-chem J 1994; 298: 629-633.
49. Plenet F, Braun L, Fautso N. Demonstration of glucose-6-phosphatase and peroxisomal catalase activity by ultra-structural cytochemistry in oval cells from livers of carcinogen-treated rats. Am j Pathol 1988; 130: 91-102.
50. Chakrabarti R, Jung CY, Lee TP, Liu H, Moorkerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral lymphocytes by phytohemagluttinin. J Immunol 1994; 152: 2660-2668.
51. Mueckler M. Facilitative glucose transporters. Eur J Bio-chem 1994; 219: 713-725.
52. Yamamoto T, Seino Y, Fukumoto H et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-230.
53. Nagamatsu S, Sawa H, Wakizaki A, Hoshino T. Expression of facilitative glucose transporter isoforms in human brain tumors. J Neurochem 1993; 61: 2048-2053.
54. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: An immunohistochem-ical study. Cancer 1993; 72: 2979-2985.
55. Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phos-phatase with respect to 3H-2-deoxyglucose retention in murine tumor models. NucI Med Biol 1996; 23: 533-541.
56. Ahn YS, Rempel A, Zerban H, Bannasch P. Over-expression of glucose transporter isoform GLUT1 and hexokinase I in rat renal oncocytic tubules and oncocytomas. Virchows Arch 1994; 425: 63-68.
57. Ahn YS, Zerban H, Bannasch P. Expression of glucose transporter isoforms (GLUT1, GLUT2) and activities of hexokinase, pyruvate kinase and malic enzyme in preneoplastic rat renal basophilic cell lesions. Virchows Arch B-Cell Pathol Incl Mol Pathol 1993; 63: 351-357.
58. Becker M, Newman S, Ismail-Beigi F. Stimulation of GLUT1 glucose transporter in response to inhibition of oxidative phosphorylation: Role of reduced sulfhydryl groups. Mol Cell Endocrinol 1996; 121: 165-170.
59. Shetty M, Ismail-Beigi N, Loeb JN, Ismail-Beigi F. Induction of GLUT1 mRNA in response to inhibition of oxidative phosphorylation. Am J Physiol 1993; 265: C1224-C1229.
60. Fisher MD, Frost SC. Translocation of GLUT1 does not account for elevated glucose transport in glucose-deprived 3T3-L1 adipocytes. J Biol Chem 1996; 271: 11806-11809.
61. Venkatesan N, Davidson MB. Differential regulation of glucose transport and glucose transporter (GLUT-1) gene expression by vanadate, phorbal ester and okadaic acid in L6 skeletal muscle cells. Biochem Mol Biol Int 1995; 37: 773-783.
62. Farese RV, Standaert ML, Arnold TP et al. Preferential activation of microsomal diacylglycerol/protein kinase C signalling during glucose treatment (de novo phospholipid synthesis) of rat adipocytes. J Clin Invest 1994; 93: 1894-1899.
63. Ortiz PA, Haspel HC. Differential control of the functional cell surface expression and content of hexose transporter GLUT-1 by glucose metabolism in murine fibroblasts. Biochem J 1993; 295: 67-72.
64. Baumann M, Jezussek D, Lang T, Richter RT, Brand K. Activities of phosphohexose isomerase and other glycolytic enzymes in normal and tumor tissue of patients with neoplastic diseases: Comparison with serum activities and correlation to tumor staging and grading. Tumour Biol 1988; 9: 281-286.
65. Lamer EH, Rutherford CL. Application of a microchemical technique to the elucidation of enzyme activity profiles within single human mammary tumours. Cancer 1978; 41: 1863-1870.
66. Bezwoda WR, Derman DP, See N, Mansoor N. Relative value of oestrogen receptor assay, lactoferrin content, and glucose-6-phosphate dehydrogenase activity as prognostic indicators in primary breast cancer. Oncology 1985; 42: 7-12.
67. Ramalingam V, Krishnamoorthy G, Govindarajulu P. Enzymes of carbohydrate metabolism in human carcinoma: Relationship with serum hormones. Neoplasma 1994; 41: 49-54.
68. Hennipman A, Smits J, van-Oirschot B et al. Glycolytic enzymes in breast cancer, benign breast disease and normal breast tissue. Tumour Biol 1987; 8: 251-263.
69. Hennipman A, Van-Oirschot BA, Smits J, Rijksen G, Staal GE. Heterogeneity of glycolytic enzyme activity and isozyme composition of pyruvate kinase in breast cancer. Tumour Biol 1988; 9: 178-189.
70. Hennipman A, Van-Oirschot BA, Smits J, Rijksen G, Staal GE. Glycolytic enzyme activities in breast cancer metastasis. Tumour Biol 1988; 9: 241-248.
71. Gudnason V, Ingvarsson S, Jonasdottir A, Andresdottir V, Egilsson V. Isoenzyme pattern and subcellular localization of hexokinases in human breast cancer and nonpatholog-ical breast tissue. Int J Cancer 1984; 34: 63-66.
72. Marshall MJ, Neal FE, Goldberg DM. Isoenzymes of hex-okinase, 6-phosphogluconate dehydrogenase, phosphoglu-comutase and lactate dehydrogenase in uterine cancer. Br j Cancer 1979; 40: 380-390.
73. Fischer G, Ruschenburg I, Eigenbrodt E, Katz N. Decrease in glucokinase and glucose-6-phosphatase and increase in hexokinase in putative preneoplastic lesions of rat liver. J Cancer Res Clin Oncol 1987; 113: 430-436.
74. Weber G. Enzymology of cancer cells. N Eng J Med 1977; 32: 623.
75. Kern KA, Norton JA. Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glu-cose. Surgery 1987; 102: 380-385.
76. Suolina EM, Haaparanta M, Paul R et al. Metabolism of 2-[(18)F]fluoro-2-deoxyglucose in tumor-bearing rats: Chromatographic and enzymatic studies. Nucl Med Biol 1986; 13: 577-581.
77. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolsm in cancer cells: Amplification of the gene encoding type II hexokinase. Cancer Res 1996; 56: 2468-2471.
78. Arora KK, Fanciulli M, Pedersen PL. Glucose phosphorylation in tumor cells: Cloning, sequencing, and overexpression in active form of a full-length cDNA encoding a mitochondrial bindable form of hexokinase. J Biol Chem 1990; 265: 6481-6488.
79. Gauthier T, Denis-Pouxviel C, Murat JC. Mitochondrial hexokinase from differentiated and undifferentiated HT29 colon cancer cells: Effect of some metabolites on the bound/soluble equilibrium. Int J Biochem 1990; 22: 419-423.
80. Oudard S, Arvelo F, Miccoli L et al. High glycolysis in glioma despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 1996; 74: 839-845.
81. Paggi MG, Fanciulli M, Del-Carlo C, Citro G, Bruno T, Floridi A. Glucose utilization by tumor cells: A post-translational modification of mitochondrial hexokinase may play a regulatory role. Biochem Biophys Res Commun 1991; 178: 648-655.
82. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995; 270: 16918-16925.
83. Rempel A, Mathupala SP, Pedersen PL. Glucose catabolism in cancer cells: Regulation of the type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett 1996; 385: 233-237.
84. Oudard S, Boitier E, Poupon A, Miccoli L, Poupon MF. Mitochondrial hexokinase, a key enzyme of cell bioenergetics: A possible target for anticancer therapy. Med Sci 1996; 11: 1121-1129.
85. Denis-Pouxviel C, Riesinger I, Buhler C, Brdiczka D, Murat JC. Regulation of mitochondrial hexokinase in cultured HT 29 human cells: An ultrastructural and biochemical study. Biochim Biophys Acta 1987; 902: 335-348.
86. Jacobs AE, Oosterhof A, Veerkamp JH. 2-Deoxy-D-glucose uptake in cultured human muscle cells. Biochim Biophys Acta 1990; 1051: 230-236.
87. Hansen PA, Gulve EA, Holloszy JO. Suitability of 2-deoxy-glucose for in vitro measurement of glucose transport in skeletal muscle. J Appl Physiol 1994; 76: 979-985.
88. Whitesell RR, Ward M, McCall AL, Granner DK, May JM. Coupled glucose transport and metabolism in cultured neoronal cells: Determination of the rate limiting step. J Cereb Blood Flow Metab 1995; 15: 814-826.
89. Board M, Humm S, Nesholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990; 265: 503-509.